| Trial ID: | L6570 |
| Source ID: | NCT02321878
|
| Associated Drug: |
Liraglutide
|
| Title: |
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide
|
| Outcome Measures: |
Primary: Number of AEs (adverse events), Week 0-52 | Secondary: Number of adverse reactions (ARs), Week 0-52|Change in HbA1c (glycosylated haemoglobin), Week 0, week 52
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1092
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2014-12-15
|
| Completion Date: |
2017-06-16
|
| Results First Posted: |
|
| Last Update Posted: |
2017-09-01
|
| Locations: |
Novo Nordisk Investigational Site, Chichibu-city, 368-0004, Japan|Novo Nordisk Investigational Site, Koriyama-shi, Fukushima, 963 8851, Japan|Novo Nordisk Investigational Site, Oyama-shi, Tochigi, 323 0022, Japan|Novo Nordisk Investigational Site, Tagajo-shi, 985 0852, Japan|Novo Nordisk Investigational Site, Tokyo, 1000005, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT02321878
|
